Brazil clinical trial regulations are entering a new era. The country’s new clinical research legislation is more than a policy change, reshaping what is possible in everyday clinics, especially for physicians and institutions that have never run a clinical trial before.

For years, Brazilian investigators lived with long, uncertain approval timelines. Sites could wait months for decisions, only to see global programs move ahead elsewhere. That uncertainty kept many clinicians on the sidelines. Law 14.874/2024 creates a different environment by establishing a national system of ethics in research with humans and setting a defined 90 business day window for the Brazilian Health Regulatory Agency (Anvisa) review of clinical trial applications that support marketing authorization. If there is no decision within that period and the trial has the required ethics approvals, clinical development can begin, which turns startup from an open question into a manageable timeline.¹

At the same time, Brazil’s scientific profile is shifting. Large scale genomic work using thousands of Brazilian genomes has shown that the country’s population is one of the most admixed and genetically diverse in the world, with substantial Indigenous, African, and European contributions and millions of previously undocumented variants.² For global sponsors who are under pressure to improve diversity in clinical development, that combination of regulatory clarity and population diversity is powerful.

For Brazilian physicians and practice leaders, these shifts raise a practical question. How can you integrate clinical research into a busy care environment in a way that benefits patients, respects new rules, and feels sustainable for your team?

What the legislation changes in day to day terms

Law 14.874 does several things that matter directly to sites. It creates the Brazilian System of Ethics in Research with Humans, defines the responsibilities of research ethics committees and a national ethics committee, and links their work to good clinical practice principles. This alignment reduces the chances that an ethically sound protocol stalls because of unclear regulatory expectations.

For clinicians, there are three concrete implications. First, predictable review periods make it easier to plan staffing, training, and patient outreach around a realistic activation date. Second, a clearer split of roles between local committees, the national body, and the health authority makes responsibilities more transparent when questions arise. Third, the law reinforces patient protections by specifying informed consent requirements, data handling, and conditions for post study access when an investigational product remains the best option, which helps physicians recommend trials with greater confidence.

The result is not a “simple” approval system. It is a system where expectations are explicit and where quality and compliance are non negotiable.

The operational learning curve for first time investigators

Predictability in law does not erase complexity at the site. New investigators still face a steep but manageable learning curve.

One part of that curve is workflow design. Trial visits do not fit naturally into existing outpatient schedules. Teams need to define how pre screening, consent, protocol mandated assessments, sample handling, and documentation fit alongside routine care. Without that planning, trials can disrupt clinic flow, frustrate staff, and delay enrollment.

Another part is infrastructure and systems. Even experienced clinicians may be new to electronic data capture platforms, remote monitoring, image uploads, and the documentation expectations that come with inspection readiness. They need clarity on who will coordinate visits, respond to queries, prepare regulatory submissions, and keep essential documents current.

Finally, there is the mindset shift from “referring to a research center” to “being a research site.” Many Brazilian physicians already send patients to external centers when public system options are exhausted. The new framework allows those same clinicians to host studies locally, keep continuity of care, and give patients earlier access to innovative therapies. The benefit is particularly strong in oncology and rare diseases, where delays in the public system can be long and follow up is critical.

Starting with a solid structure is essential. It is difficult to bolt on quality systems and documentation habits after a trial is running, and the new legislation makes noncompliance subject to both ethical and health infractions, with potential professional and regulatory sanctions.

How site enablement support fits into Brazil’s new era

For many practices, the constraint is not interest but capacity. Physicians may be enthusiastic about research and clear on the benefits for patients, yet understandably hesitant about taking on feasibility questionnaires, budgets, contracts, submissions, monitoring visits, and data entry in addition to their clinical work.

This is where structured site enablement becomes central. The goal is not to remove investigators from research. It is to let them focus on medical care and study decisions while a dedicated coordinator supports documentation, scheduling, and regulatory workflows.

For Brazilian physicians and institutions who are curious but unsure where to start, the combination of a clearer legislative framework, global demand for diverse research populations, and coordinated operational support creates a realistic path into clinical trials. It becomes possible to build research into everyday care, reach underrepresented patients, and contribute to evidence that reflects Brazil rather than relying only on data generated elsewhere.

If you are exploring what a first or expanded trial program could look like for your practice in Brazil, Milestone One supports clinical trial startup and day to day activities by providing site enablement services, including an on-site research coordinator who supports key operational tasks and administrative responsibilities to help ease your workload and support strong enrollment and study quality.

To learn how Milestone One can support you in navigating complexity, taking on additional studies, or getting started with research for the first time, reach out to the Milestone One team.

References

1. Brazil. Law No. 14.874, of 28 May 2024. Provides for research involving humans and establishes the Brazilian System of Ethics in Research involving Humans. Official English translation published by Anvisa. Available at: https://www.gov.br/anvisa/en/rules-and-regulations/arquivos/lei-14874-2024-e.pdf.

2. Kelly Nunes et al., Admixture’s impact on Brazilian population evolution and health.Science388,eadl3564(2025).DOI:10.1126/science.adl3564